CEO Ryan Spencer was paid $8,210,775 in fiscal year 2024, ↑ up 41.3% from fiscal year 2023, the 32nd percentile of its disclosed peer group (SEC filing 0000930413-25-001273 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,210,775 ↑ Ryan Spencer total, FY2024 | 32nd CEO pay percentile vs peers | — CEO-to-median pay ratio | 92.38% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ryan Spencer | $835,001 | $0 | $4,902,150 | $1,824,299 | $641,907 | $0 | $7,418 | $8,210,775 |
| Chief Executive Officer and Director | ||||||||
| David Novack | 593,108 | 0 | 2,016,121 | 750,253 | 364,762 | 0 | 7,443 | 3,731,687 |
| President and Chief Operating Officer | ||||||||
| John Slebir | 530,000 | 0 | 1,485,500 | 552,818 | 271,625 | 0 | 7,504 | 2,847,447 |
| Senior Vice President and General Counsel | ||||||||
| Kelly MacDonald | 480,098 | 6,642 | 1,379,435 | 513,331 | 239,408 | 0 | 7,353 | 2,626,267 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Robert Janssen | 542,291 | 0 | 1,060,944 | 394,870 | 277,924 | 0 | 7,504 | 2,283,533 |
| Chief Medical Officer and Senior Vice President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Ryan Spencer | $8,210,775 | $5,810,736 | $5,594,000 | ↑ +2,400,039 |
| David Novack | 3,731,687 | 2,993,331 | 2,779,823 | ↑ +738,356 |
| John Slebir | 2,847,447 | — | — | — |
| Kelly MacDonald | 2,626,267 | 2,065,805 | 1,793,266 | ↑ +560,462 |
| Robert Janssen | 2,283,533 | 1,883,323 | 1,710,780 | ↑ +400,210 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Dynavax Technologies's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper DVAX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name DVAX as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2024 total |
|---|---|---|
| John Slebir | General Counsel | $2,847,447 |
| Kelly MacDonald | CFO | $2,626,267 |
| Robert Janssen | SVP | $2,283,533 |
| Ryan Spencer | CEO | $8,210,775 |
| David Novack | President | $3,731,687 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Brent MacGregor | Independent Director | $285,637 |
| Daniel L. Kisner | Independent Director | $297,637 |
| Elaine Sun | Independent Director | $290,637 |
| Emilio Emini | Independent Director | — |
| Francis R. Cano | Independent Director | $285,637 |
| Julie Eastland | Independent Director | $300,637 |
| Lauren Silvernail | Independent Director | — |
| Peggy V. Phillips | Independent Director | $305,637 |
| Peter R. Paradiso | Independent Director | $302,387 |
| Scott Myers | Chair of the Board | $330,637 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-05-12 | A | 38,182 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-05-12 | A | 31,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Brent MacGregor | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Elaine Sun | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Emilio Emini | Director | 2025-06-11 | A | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Emilio Emini | Director | 2025-06-11 | A | 1,439 | 0 | 0 | Common | Form 4 ↗ |
| Peter R. Paradiso | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter R. Paradiso | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2025-06-11 | A | 5,758 | 0 | 0 | Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2025-06-11 | A | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2025-06-11 | A | 1,439 | 0 | 0 | Common | Form 4 ↗ |
| Scott Myers | Director | 2025-06-11 | A | 28,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2025-08-21 | D | 1,094,994 | 11 | 12,077,784 | Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2025-08-22 | D | 970,143 | 11 | 10,273,814 | Common | Form 4 ↗ |
| Scott Myers | Director | 2025-08-22 | A | 3,800 | 11 | 41,116 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | D | 22,620 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 16,667 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 33,750 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 18,788 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | D | 15,477 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 14,141 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 15,477 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-23 | D | 12,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | D | 45,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 156,250 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 22,620 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | D | 16,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | A | 60,625 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 45,333 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-23 | A | 12,727 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | D | 14,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-23 | D | 18,788 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-23 | A | 55,000 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-23 | A | 37,500 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | A | 14,141 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-23 | D | 14,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-12-24 | D | 138,168 | 15 | 2,125,024 | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2025-12-24 | D | 32,502 | 15 | 499,881 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 48,107 | 15 | 739,886 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | A | 10,000 | 10 | 104,700 | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2025-12-24 | D | 5,598 | 15 | 86,097 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | A | 20,000 | 7 | 136,100 | Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2025-12-24 | D | 30,000 | 15 | 464,700 | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2025-12-24 | D | 36,141 | 15 | 555,849 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 85,655 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 114,000 | 16 | 1,782,960 | Common, open-market sale | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 8,345 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | A | 94,000 | 10 | 984,180 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-01-15 | A | 20,000 | 7 | 136,100 | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 37,576 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 22,620 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 93,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 56,364 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 42,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 21,829 | — | — | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 1,500 | — | — | Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 11,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 16,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 45,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 31,204 | — | — | Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 3,800 | — | — | Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 42,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 350,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 46,430 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 25,455 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 7,129 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 28,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 16,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 88,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | A | 42,424 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 69,634 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | A | 136,000 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 379,620 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | A | 56,364 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 63,334 | — | — | Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | A | 67,860 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 42,663 | — | — | Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel L. Kisner | Director | 2026-02-10 | D | 21,829 | — | — | Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 45,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 29,865 | — | — | Common | Form 4 ↗ |
| Scott Myers | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 90,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 42,424 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 50,000 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | A | 50,000 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 280,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 165,000 | — | — | Common | Form 4 ↗ |
| Deep Track Biotechnology Master Fund, Ltd. | Greater-than-10% holder | 2026-02-10 | D | 15,726,349 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 130,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 67,860 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 42,424 | — | — | Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 7,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 350,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 95,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Novack | President & COO | 2026-02-10 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 90,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 231,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | D | 136,000 | — | — | Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-02-10 | A | 165,000 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | A | 42,424 | — | — | Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 28,283 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 15,476 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | A | 46,430 | — | — | Common | Form 4 ↗ |
| Emilio Emini | Director | 2026-02-10 | D | 10,075 | — | — | Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis R. Cano | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brent MacGregor | Director | 2026-02-10 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 7,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Silvernail | Director | 2026-02-10 | D | 10,075 | — | — | Common | Form 4 ↗ |
| John Slebir | SVP General Counsel | 2026-02-10 | D | 300,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Elaine Sun | Director | 2026-02-10 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kelly MacDonald | SVP and CFO | 2026-02-10 | D | 60,204 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Metzinger | VP, Chief Accounting Officer | 2026-02-10 | D | 31,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Robert Janssen | OPTION | 2024-02-15 | — | — | 50,000 | — | $394,870 |
| David Novack | OPTION | 2024-02-15 | — | — | 95,000 | — | 750,253 |
| John Slebir | OPTION | 2024-02-15 | — | — | 70,000 | — | 552,818 |
| Ryan Spencer | PSU | 2024-02-15 | 82,500 | 165,000 | — | 330,000 | 2,842,950 |
| Kelly MacDonald | PSU | 2024-02-15 | 23,215 | 46,430 | — | 92,860 | 799,989 |
| Robert Janssen | — | 2024-02-15 | — | — | 35,710 | — | 445,661 |
| David Novack | — | 2024-02-15 | — | — | 67,860 | — | 846,893 |
| Kelly MacDonald | — | 2024-02-15 | — | — | 46,430 | — | 579,446 |
| Ryan Spencer | — | 2024-02-15 | — | — | 165,000 | — | 2,059,200 |
| John Slebir | — | 2024-02-15 | — | — | 50,000 | — | 624,000 |
| David Novack | PSU | 2024-02-15 | 33,930 | 67,860 | — | 135,720 | 1,169,228 |
| John Slebir | PSU | 2024-02-15 | 25,000 | 50,000 | — | 100,000 | 861,500 |
| Kelly MacDonald | OPTION | 2024-02-15 | — | — | 65,000 | — | 513,331 |
| Ryan Spencer | OPTION | 2024-02-15 | — | — | 231,000 | — | 1,824,299 |
| Robert Janssen | PSU | 2024-02-15 | 17,855 | 35,710 | — | 71,420 | 615,283 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Robert Janssen | $0 | $615,283 | $394,870 | 60.9% |
| David Novack | 0 | 1,169,228 | 750,253 | 60.9% |
| John Slebir | 0 | 861,500 | 552,818 | 60.9% |
| Ryan Spencer | 0 | 2,842,950 | 1,824,299 | 60.9% |
| Kelly MacDonald | 0 | 799,989 | 513,331 | 60.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Slebir | PSU | 27,000 | — | $344,790 |
| David Novack | RSU | 67,860 | — | 866,572 |
| Kelly MacDonald | PSU | 46,430 | — | 592,911 |
| Robert Janssen | PSU | 35,710 | — | 456,017 |
| Robert Janssen | RSU | 35,710 | — | 456,017 |
| Ryan Spencer | PSU | 165,000 | — | 2,107,050 |
| David Novack | PSU | 67,860 | — | 866,572 |
| John Slebir | Option | 34,222 | 11.12 | — |
| Ryan Spencer | Option | 108,890 | 11.12 | — |
| John Slebir | RSU | 4,666 | — | 59,585 |
| John Slebir | Option | 70,000 | 12.48 | — |
| Ryan Spencer | PSU | 62,500 | — | 798,125 |
| Kelly MacDonald | Option | 5,028 | 12.74 | — |
| John Slebir | PSU | 14,000 | — | 178,780 |
| Ryan Spencer | RSU | 20,833 | — | 266,037 |
| David Novack | PSU | 26,500 | — | 338,405 |
| Kelly MacDonald | PSU | 16,000 | — | 204,320 |
| Robert Janssen | PSU | 24,000 | — | 306,480 |
| Kelly MacDonald | RSU | 5,333 | — | 68,102 |
| Ryan Spencer | Option | 231,000 | 12.48 | — |
| Robert Janssen | RSU | 4,333 | — | 55,332 |
| Kelly MacDonald | Option | 65,000 | 12.48 | — |
| David Novack | Option | 95,000 | 12.48 | — |
| Ryan Spencer | RSU | 165,000 | — | 2,107,050 |
| John Slebir | RSU | 50,000 | — | 638,500 |
| David Novack | RSU | 8,833 | — | 112,797 |
| Robert Janssen | Option | 4,167 | 12.74 | — |
| John Slebir | Option | 4,445 | 12.74 | — |
| Kelly MacDonald | RSU | 46,430 | — | 592,911 |
| Robert Janssen | Option | 31,111 | 11.12 | — |
| John Slebir | PSU | 50,000 | — | 638,500 |
| Ryan Spencer | PSU | 125,000 | — | 1,596,250 |
| Kelly MacDonald | PSU | 30,000 | — | 383,100 |
| David Novack | PSU | 48,500 | — | 619,345 |
| Robert Janssen | PSU | 13,000 | — | 166,010 |
| Ryan Spencer | Option | 19,445 | 12.74 | — |
| Kelly MacDonald | Option | 38,890 | 11.12 | — |
| David Novack | Option | 58,334 | 11.12 | — |
| David Novack | Option | 8,334 | 12.74 | — |
| Robert Janssen | Option | 50,000 | 12.48 | — |
We believe our NEOs' compensation should align our executives' interests with that of our stockholders over the long-term through achievement of strategic corporate objectives that are fundamental to our business and that are intended to create long-term stockholder value. Our executive compensation programs are designed to be competitive within our industry and within our peer group to enable us to attract, motivate, reward, and retain outstanding talent.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-11 | 88,358,585 | 7,283,834 | 938,871 | 92.38% | Passed |
| 2024 | 2024-04-11 | 88,138,468 | 3,105,543 | 232,291 | 96.35% | Passed |
| 2023 | 2023-05-26 | 76,588,270 | 6,298,635 | 403,756 | 92.4% | Passed |
| 2022 | 2022-04-04 | 67,697,574 | 4,551,027 | 272,285 | 93.7% | Passed |
| 2021 | 2021-04-06 | 52,481,077 | 2,483,790 | 268,274 | 95.02% | Passed |
| 2020 | 2020-05-28 | 46,279,881 | 3,848,208 | 201,991 | 91.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-11 | 92.38%a |
| 2024 | 2024-04-11 | 96.35%b |
| 2023 | 2023-05-26 | 92.4%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions have the same effect as negative votes.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Scott MyersIndependent · Board Chair · Compensation (Chair) | $100,000 | $63,480 | $167,157 | $0 | $0 | $330,637 |
| Peggy V. PhillipsIndependent · Audit · Compensation (Chair) · Not standing for re-election | 75,000 | 63,480 | 167,157 | 0 | 0 | 305,637 |
| Peter R. ParadisoIndependent · Compensation | 71,750 | 63,480 | 167,157 | 0 | 0 | 302,387 |
| Julie EastlandIndependent · Audit (Chair) · Not standing for re-election | 70,000 | 63,480 | 167,157 | 0 | 0 | 300,637 |
| Daniel L. KisnerIndependent · Nominating/Governance (Chair) · Compensation | 67,000 | 63,480 | 167,157 | 0 | 0 | 297,637 |
| Elaine SunIndependent · Audit | 60,000 | 63,480 | 167,157 | 0 | 0 | 290,637 |
| Brent MacGregorIndependent · Nominating/Governance | 55,000 | 63,480 | 167,157 | 0 | 0 | 285,637 |
| Francis R. CanoIndependent · Nominating/Governance | 55,000 | 63,480 | 167,157 | 0 | 0 | 285,637 |
| Lauren SilvernailIndependent · Audit (Chair) · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Ryan SpencerEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Emilio EminiIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $553,750 |
| Equity awards (grant-date value) | $507,840 |
| All other compensation | $0 |
| Total cost of the board | $1,061,590 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Dynavax Technologies names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Dynavax Technologies.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 4 | Corcept Therapeutics, Inc. | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 5 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 6 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 7 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 8 | Eagle Pharmaceuticals, Inc. | 2022 | Scott Tarriff | 848,940 | 9,011,197 | 0 | 636,705 | 10,520,577 |
| 9 | Mannkind Corp. | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 10 | Novavax, Inc. | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 11 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 13 | Acadia Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Harmony Biosciences, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 16 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 17 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 18 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 19 | Collegium Pharmaceuticals, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 20 | Agenus, Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Acadia Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agenus, Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Collegium Pharmaceuticals, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics, Inc. | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Eagle Pharmaceuticals, Inc. | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Harmony Biosciences, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Mannkind Corp. | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Novavax, Inc. | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Ryan Spencer | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Executive Compensation”. As printed: 8,210,775. Filing ↗ |
| 2 | Section 01, David Novack | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Executive Compensation”. As printed: 3,731,687. Filing ↗ |
| 3 | Section 01, John Slebir | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Executive Compensation”. As printed: 2,847,447. Filing ↗ |
| 4 | Section 01, Kelly MacDonald | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Executive Compensation”. As printed: 2,626,267. Filing ↗ |
| 5 | Section 01, Robert Janssen | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Executive Compensation”. As printed: 2,283,533. Filing ↗ |
| 6 | Section 03, Robert Janssen OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 7 | Section 03, David Novack OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 8 | Section 03, John Slebir OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 9 | Section 03, Ryan Spencer PSU | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 10 | Section 03, Kelly MacDonald PSU | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 11 | Section 03, Robert Janssen | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 12 | Section 03, David Novack | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 13 | Section 03, Kelly MacDonald | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 14 | Section 03, Ryan Spencer | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 15 | Section 03, John Slebir | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 16 | Section 03, David Novack PSU | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 17 | Section 03, John Slebir PSU | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 18 | Section 03, Kelly MacDonald OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 19 | Section 03, Ryan Spencer OPTION | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 20 | Section 03, Robert Janssen PSU | DEF 14A | — | — | Section “Executive Compensation” · grants of plan-based awards table. |
| 21 | Section 08, Scott Myers | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 330,637. Filing ↗machine: t119 · r1 · c15 · span 345275–345282 |
| 22 | Section 08, Peggy V. Phillips | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 305,637. Filing ↗machine: t119 · r7 · c15 · span 357174–357181 |
| 23 | Section 08, Peter R. Paradiso | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 302,387. Filing ↗machine: span 355197–355204 |
| 24 | Section 08, Julie Eastland | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 300,637. Filing ↗machine: t119 · r3 · c15 · span 349242–349249 |
| 25 | Section 08, Daniel L. Kisner | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 297,637. Filing ↗machine: span 351224–351231 |
| 26 | Section 08, Elaine Sun | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 290,637. Filing ↗machine: t119 · r8 · c15 · span 359144–359151 |
| 27 | Section 08, Brent MacGregor | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 285,637. Filing ↗machine: t119 · r5 · c15 · span 353199–353206 |
| 28 | Section 08, Francis R. Cano | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 285,637. Filing ↗machine: span 347268–347275 |
| 29 | Section 08, Lauren Silvernail | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 08, Ryan Spencer | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 31 | Section 08, Emilio Emini | DEF 14A | 2025-04-17 | 0000930413-25-001273 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 02, Joseph Anthony Metzinger 2025-05-12 | Form 4 | 2025-05-13 | 0001029142-25-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Joseph Anthony Metzinger 2025-05-12 | Form 4 | 2025-05-13 | 0001029142-25-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Scott Myers 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Francis R. Cano 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Francis R. Cano 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Brent MacGregor 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Brent MacGregor 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Elaine Sun 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Elaine Sun 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Emilio Emini 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000098 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Emilio Emini 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000098 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Peter R. Paradiso 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Peter R. Paradiso 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Daniel L. Kisner 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Daniel L. Kisner 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Lauren Silvernail 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Lauren Silvernail 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Scott Myers 2025-06-11 | Form 4 | 2025-06-13 | 0001029142-25-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-21 | Form 4 | 2025-08-22 | 0000950170-25-111070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Deep Track Biotechnology Master Fund, Ltd. 2025-08-22 | Form 4 | 2025-08-22 | 0000950170-25-111070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Scott Myers 2025-08-22 | Form 4 | 2025-08-25 | 0001029142-25-000120 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, David Novack 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Ryan Spencer 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, John Slebir 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, John Slebir 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, David Novack 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Kelly MacDonald 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Kelly MacDonald 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Kelly MacDonald 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Joseph Anthony Metzinger 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058989 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Ryan Spencer 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Ryan Spencer 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, David Novack 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, John Slebir 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, David Novack 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Ryan Spencer 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Joseph Anthony Metzinger 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058989 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Kelly MacDonald 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, David Novack 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Ryan Spencer 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Kelly MacDonald 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, John Slebir 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, John Slebir 2025-12-23 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Ryan Spencer 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058969 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, John Slebir 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058979 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Joseph Anthony Metzinger 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058989 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, David Novack 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Kelly MacDonald 2025-12-24 | Form 4 | 2025-12-29 | 0001628280-25-058992 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, David Novack 2026-01-15 | Form 4 | 2026-01-20 | 0001628280-26-002640 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Lauren Silvernail 2026-02-10 | Form 4 | 2026-02-10 | 0001225755-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Emilio Emini 2026-02-10 | Form 4 | 2026-02-10 | 0002054163-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Joseph Anthony Metzinger 2026-02-10 | Form 4 | 2026-02-10 | 0002067729-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Joseph Anthony Metzinger 2026-02-10 | Form 4 | 2026-02-10 | 0002067729-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Daniel L. Kisner 2026-02-10 | Form 4 | 2026-02-10 | 0001073407-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Scott Myers 2026-02-10 | Form 4 | 2026-02-10 | 0001356256-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Deep Track Biotechnology Master Fund, Ltd. 2026-02-10 | Form 4 | 2026-02-11 | 0001193125-26-046675 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Emilio Emini 2026-02-10 | Form 4 | 2026-02-10 | 0002054163-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, David Novack 2026-02-10 | Form 4 | 2026-02-10 | 0001573072-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Ryan Spencer 2026-02-10 | Form 4 | 2026-02-10 | 0001777938-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Emilio Emini 2026-02-10 | Form 4 | 2026-02-10 | 0002054163-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Francis R. Cano 2026-02-10 | Form 4 | 2026-02-10 | 0001286710-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Brent MacGregor 2026-02-10 | Form 4 | 2026-02-10 | 0001818951-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Lauren Silvernail 2026-02-10 | Form 4 | 2026-02-10 | 0001225755-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Lauren Silvernail 2026-02-10 | Form 4 | 2026-02-10 | 0001225755-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, John Slebir 2026-02-10 | Form 4 | 2026-02-10 | 0001475990-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Elaine Sun 2026-02-10 | Form 4 | 2026-02-10 | 0001805339-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Kelly MacDonald 2026-02-10 | Form 4 | 2026-02-10 | 0001781117-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Joseph Anthony Metzinger 2026-02-10 | Form 4 | 2026-02-10 | 0002067729-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0001193125-25-141755 | Item 5.07 · say-on-pay result. As reported: 92.38% (votes for as printed: 88,358,585). Filing ↗ |
| 190 | Section 06, 2024 vote | Form 8-K | 2024-05-24 | 0000950170-24-064556 | Item 5.07 · say-on-pay result. As reported: 96.35% (votes for as printed: 88,138,468). Filing ↗ |
| 191 | Section 06, 2023 vote | Form 8-K | 2023-05-26 | 0000950170-23-024566 | Item 5.07 · say-on-pay result. As reported: 92.4% (votes for as printed: 76,588,270). Filing ↗ |
| 192 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 193 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 194 | Section 09b board cost (computed) | Computed | — | — | Cash 553,750 + equity 507,840 + all other 0 = 1,061,590, summed across the director compensation table rows.machine: formula: Σ = 1,061,590 |
| 195 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 196 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 197 | Supernus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 198 | Corcept Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics, Inc.'s own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 199 | Vaxcyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 200 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 201 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 202 | Eagle Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2023-05-01 | 0001104659-23-054338 | CEO total compensation as printed in Eagle Pharmaceuticals, Inc.'s own proxy. As printed: 10,520,577. Filing ↗machine: r1 · c47 · span 689556–689566 |
| 203 | Mannkind Corp., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145613 | CEO total compensation as printed in Mannkind Corp.'s own proxy. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621 |
| 204 | Novavax, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027328 | CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394 |
| 205 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 206 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 207 | Acadia Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in Acadia Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 208 | Dynavax Technologies (subject), Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗ |
| 209 | Harmony Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 210 | Vir Biotechnology, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025379 | CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922 |
| 211 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 212 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191 |
| 213 | Collegium Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceuticals, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 214 | Agenus, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197536 | CEO total compensation as printed in Agenus, Inc.'s own proxy. As printed: 1,350,325. Filing ↗machine: r2 · c21 · span 404620–404629 |
| 215 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 216 | Section 10a, Agenus, Inc. reciprocity | DEF 14A | — | 0001193125-26-197536 | Agenus, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 217 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 218 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 219 | Section 10a, Supernus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 220 | Section 10a, Collegium Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 221 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 222 | Section 10a, Ironwood Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-050325 | Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 223 | Section 10a, Vaxcyte, Inc. reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 224 | Section 10a, Mannkind Corp. reciprocity | DEF 14A | — | 0001193125-26-145613 | Mannkind Corp.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 225 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 226 | Section 10a, Harmony Biosciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 227 | Section 10a, Eagle Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-23-054338 | Eagle Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 228 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 229 | Section 10a, Acadia Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | Acadia Pharmaceuticals, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 230 | Section 10a, Novavax, Inc. reciprocity | DEF 14A | — | 0001628280-26-027328 | Novavax, Inc. names Dynavax Technologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 231 | Section 10a, Vir Biotechnology, Inc. reciprocity | DEF 14A | — | 0001628280-26-025379 | Vir Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
| 232 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Dynavax Technologies. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.